Features include very common findings: Onychogryphosis, Fragile nails, and Nail dystrophy; and common findings: Dystrophic toenail, Dystrophic fingernails, Onychogryphosis of toenails, and Onychogryphosis of fingernail. 8 total HPO annotations.

Biomarker and diagnostic research for dystrophic epidermolysis bullosa, nails only has been reported in the published literature.

2 FDA-approved treatments are available for dystrophic epidermolysis bullosa, nails only, including Prademagene zamikeracel (zevaskyn, approved 2025) and beremagene geperpavec-svdt (VYJUVEK, approved 2023).

Approved Therapies

Phenotype severity distribution: 3 very common features, 4 common features.

Estimated prevalence: <1 in 1,000,000 (VERY_RARE).

No clinical trials have been registered for dystrophic epidermolysis bullosa, nails only.

3 publications have been identified in PubMed for dystrophic epidermolysis bullosa, nails only. Research spans Diagnostic / Biomarker (33%), Review / Meta-Analysis (33%), and Case Report / Case Series (33%).

Recent Publications

• Sun F (2025). [PMID: 41244805](https://pubmed.ncbi.nlm.nih.gov/41244805/). *Frontiers in medicine*. [Case Report / Case Series]

• Bighetti S (2025). [PMID: 40844377](https://pubmed.ncbi.nlm.nih.gov/40844377/). *Dermatology reports*. [Review / Meta-Analysis]

• Öktem A (2024). [PMID: 38828627](https://pubmed.ncbi.nlm.nih.gov/38828627/). *Clinical and experimental dermatology*. [Diagnostic / Biomarker]